TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT06121011: A Global Prospective Observational Registry of Patients With Pompe Disease

Sponsor: Amicus Therapeutics · Phase: PHASE2 · Area: RARE_ORPHAN · Target Enrollment: 500 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$9,321,500

Rescue Site Savings

+$6,128,500

Unlock Full NCT06121011 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06121011 Rescue Dossier →